# Opioid Crisis Timeline A chronological reference for the most lethal pharmaceutical disaster in American history. From 1999 through 2024, US opioid-overdose deaths exceeded **800,000** — more Americans than died in World War II, Vietnam, and the [[Korean War]] combined. The crisis was not a natural epidemic. It was manufactured: a deliberate commercial strategy executed by a single family-controlled drug company over three decades, with the cooperation of federal regulators, prescribing physicians, professional medical societies, hospital accreditation bodies, the world's largest management consultancy, and three Big-Three drug distributors who together moved billions of pills into towns whose populations they exceeded. This is also the timeline of how the legal system processed — and ultimately did not punish — the people who profited. No member of the [[Sackler Family]] has served a day in prison. The 2024 Supreme Court ruling in [[Harrington v. Purdue Pharma]] forced a renegotiation that stripped the family of bankruptcy-court immunity, but the **$7.4 billion** 2025 settlement is still paid out of profits the Sacklers extracted *before* the bankruptcy filing — at least **$11 billion** had been moved out of [[Purdue Pharma]] to family-controlled trusts and offshore entities between 2008 and 2019. The through-line: a family that revolutionized the *marketing* of pharmaceuticals in the 1950s used the same playbook in the 1990s for a drug whose addictive properties they understood — and the regulatory, professional, and journalistic infrastructure that should have stopped them was bought, captured, or bypassed. --- ## Era 1 — The Arthur Sackler Foundations (1952–1987) The crisis that would kill 800,000 Americans began with a marketing innovation by [[Arthur Sackler]] in the 1950s. Arthur was not the Purdue executive who launched [[OxyContin]] — he died in 1987, nearly a decade before OxyContin's release, and his branch of the family was bought out of [[Purdue Pharma]] before the OxyContin era. But the *techniques* the company used to sell OxyContin were Arthur's techniques. - **1952 — Sackler brothers buy Purdue Frederick.** Arthur, Mortimer, and Raymond Sackler — three Brooklyn-born physicians, sons of Jewish immigrants from Galicia and Poland — purchase the small, struggling Purdue Frederick Company in lower Manhattan for **$50,000**. Purdue Frederick was a generic-pharmaceutical maker founded in 1892, best known for laxatives and earwax remover. The brothers had been making their living in psychiatry, medical research, and (Arthur's specialty) pharmaceutical advertising. Arthur, the eldest, was 39. - **1950s–60s — Arthur Sackler revolutionizes pharmaceutical marketing.** While his brothers ran Purdue Frederick, Arthur built an empire on the *promotion* side at the William Douglas McAdams advertising agency. His innovations are now standard practice: direct-to-physician marketing (rather than direct-to-consumer or pharmacist-mediated); full-page color ads in the *Journal of the American Medical Association*; sponsored "educational" content; the use of doctor-endorsers; and the deployment of pharmaceutical sales reps who carried drug samples and gifts directly into physician offices. Arthur was inducted into the Medical Advertising Hall of Fame, which credited him with shaping "pharmaceutical promotion as we know it today." - **1963 — Valium becomes the first $100M drug.** Arthur Sackler's McAdams agency runs the marketing for Roche's Valium (diazepam) and its precursor Librium. Valium becomes the most-prescribed drug in America from 1968 to 1982 and the first pharmaceutical to top $100 million in annual sales. Arthur takes commission. Critics later argue that Valium prefigured the OxyContin playbook: a drug marketed as safer and less addictive than predecessors, prescribed at massive scale, and producing a widespread dependency epidemic (the "Mother's Little Helper" benzodiazepine wave of the 1960s–70s). Patrick Radden Keefe's *[[Empire of Pain]]* makes this argument explicit; the Sackler heirs dispute it. - **1960 — Arthur Sackler founds the Medical Tribune.** A weekly medical newspaper that eventually reaches 600,000 physicians. The Tribune blurs the line between editorial content and pharma marketing — a model that medical publishing would adopt broadly. Arthur's three companies (advertising, publishing, and pharma) function as an integrated commercial ecosystem aimed at the prescribing physician. - **1972 — MS Contin patent.** Purdue acquires the technology that will eventually underpin its opioid empire: a controlled-release oral formulation initially developed in the UK. The company's UK affiliate Napp Pharmaceuticals launches MS Contin (controlled-release morphine sulfate) for cancer pain in 1980. MS Contin establishes Purdue's reputation as a respected pain-management company and generates the cash that funds [[OxyContin]] development. By the late 1980s MS Contin is bringing in $170M+ annually, primarily for terminal cancer patients. - **1987 — Arthur Sackler dies (age 73).** His one-third stake in the family enterprise is bought out by his brothers Mortimer and Raymond for **$22.35 million** (ProPublica). Arthur's branch of the family — his widow Jillian, his children from earlier marriages — formally exits the Purdue ownership structure before OxyContin is developed. They will later argue (and continue to argue) that Arthur's descendants bear no responsibility for the opioid crisis. *ProPublica* reporting suggests Arthur's heirs may nonetheless have profited from OxyContin indirectly through retained interests in international affiliates. The two factions of the family — Arthur's branch and the Purdue Sacklers (Mortimer's family, "Side A" in the bankruptcy, and Raymond's, "Side B") — have been estranged for decades and now actively repudiate each other. - **1980s — The pain management movement begins.** A coalition of pain specialists, palliative-care advocates, hospice physicians, and patient groups begins arguing that American medicine systematically *undertreats* pain — particularly cancer pain and chronic non-malignant pain. The arguments are largely correct as applied to terminal illness. They are then extended, with much less evidence, to non-cancer chronic pain. Key figure: Dr. Russell Portenoy at Memorial Sloan Kettering, who in a series of papers and lectures will argue that opioids can be safely used long-term in non-cancer patients, that addiction is rare in pain patients, and that the medical profession's "opiophobia" is itself a public-health problem. Portenoy received funding from Purdue and other opioid manufacturers; he later (2012) acknowledged that the evidence base for his earlier claims had been thin. - **1986 — Foley & Portenoy paper.** Kathleen Foley and Russell Portenoy publish "Chronic use of opioid analgesics in non-malignant pain: report of 38 cases" in *Pain*. The paper finds low addiction rates among the 38 patients — a sample size that should not have supported the conclusions later drawn from it. This and a 1980 one-paragraph letter to the *New England Journal of Medicine* by Porter & Jick (analyzing hospital inpatient records) would become the two most-cited "studies" purportedly showing that medical opioid use does not cause addiction. Both would be cited in [[OxyContin]] marketing for years. --- ## Era 2 — Pain as the Fifth Vital Sign (1990–1995) - **1991 — Purdue Frederick rebrands as Purdue Pharma.** Raymond Sackler serves as president. His son [[Richard Sackler]] — Yale Medical School, no clinical practice — joins Purdue in increasingly senior positions through the early 1990s and emerges as the driving force behind the company's opioid push. - **1990s — The "pain as the fifth vital sign" campaign.** The American Pain Society begins promoting the idea that pain should be measured and treated alongside the four traditional vital signs (temperature, pulse, respiration, blood pressure). The Joint Commission on Accreditation of Healthcare Organizations (now The Joint Commission) — the body that accredits US hospitals — incorporates pain assessment standards into its accreditation requirements (initially 1999, expanded through the 2000s). Hospitals are now graded on whether they aggressively treat patient-reported pain. The institutional pressure to *prescribe more opioids* becomes structural, not just commercial. - **1990s — Front groups proliferate.** The American Pain Foundation, the American Academy of Pain Medicine, the American Pain Society, the Joint Commission's Pain Management Standards working group — many receive substantial funding from Purdue and other opioid manufacturers. Disclosure norms in 1990s American medicine are weak; the funding is often invisible to prescribing physicians. A 2012 US [[Senate Finance Committee]] investigation will catalog the scale of this funding ecosystem. - **1995 — "Pseudoaddiction" enters the lexicon.** A term coined in a 1989 paper by David Haddox (who later joins Purdue as a medical director) and now actively promoted: the idea that patients who appear to be addicts seeking more drugs may simply be *undertreated for pain*, and that the correct response to apparent drug-seeking behavior is to **increase** the dose, not decrease it. The concept has no rigorous evidence base. It functions as a tool to keep prescriptions escalating in patients showing clear addiction signals. The term will appear in Purdue training materials throughout the OxyContin era. - **1995-12-12 — FDA approves OxyContin.** Curtis Wright, the FDA medical examiner who handled the OxyContin application, approves the drug with a remarkable label claim: "Delayed absorption as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug." There is no clinical-trial evidence for this. The phrase was suggested by Purdue. Two years later, Curtis Wright leaves the FDA and joins Purdue Pharma as a medical executive at roughly triple his federal salary — the [[Revolving Door]] in textbook form. The label language remains until 2001, when (under FDA pressure) it is removed. --- ## Era 3 — OxyContin Launch and the First Wave (1996–2006) - **1996 — OxyContin launches.** Purdue Pharma brings [[OxyContin]] to market with the largest pharmaceutical marketing campaign in industry history to that date. The drug is a controlled-release formulation of oxycodone — a semi-synthetic opioid roughly twice as potent as morphine, derived from the opium-poppy alkaloid thebaine. The clinical promise: 12-hour pain relief without the peaks-and-troughs of immediate-release oxycodone, and (allegedly) reduced addictive potential because the delayed release would prevent the rapid blood-level spike thought to drive the euphoria-and-craving cycle. First-year sales target ($48M) is hit four months early. [[Richard Sackler]], by now a senior Purdue executive, sends an internal email celebrating: "We have to hammer on abusers in every way possible. They are the culprits and the problem. They are reckless criminals." - **1996–2001 — The aggressive marketing campaign.** Purdue spends roughly **6–12× more** promoting OxyContin in its first six years than it spent on MS Contin in its first six years (and substantially more than competitors spent on their lead products). The campaign deploys: - A sales force that grows from 318 reps (1996) to over 1,000 (2001), targeting the highest-prescribing physicians - More than 40 all-expenses-paid pain-management symposia at resorts in Florida, Arizona, and California (1996–2001), training 5,000+ physicians, pharmacists, and nurses as Purdue speaker-bureau members - A reprint and patient-coupon program offering free 7-day or 30-day OxyContin starter prescriptions - Branded promotional materials (mugs, hats, fishing hats, plush toys, a "Get In The Swing With OxyContin" CD) distributed to physicians - The repeated, evidence-free claim that the addiction risk is "less than 1 percent" - The promotion of the **80mg pill** — far higher than the doses used in any other oral opioid — to medical professionals as appropriate for routine chronic pain - **1996–2000 — Sales explode.** OxyContin revenue grows from **$48 million in 1996 to $1.1 billion in 2000**. By 2001, OxyContin accounts for ~80% of Purdue Pharma's revenue. Purdue and the Sacklers become billionaires. - **2000 — The first OxyContin epidemic stories.** Rural Appalachia — eastern Kentucky, southern West Virginia, southwestern Virginia, southeastern Ohio — becomes the first identified epicenter. The drug, easily crushed to defeat the time-release coating and then snorted or injected, finds an enormous illicit market. Local pharmacists and physicians report waves of armed robberies of pain clinics. The street name "hillbilly heroin" enters circulation. Local prosecutors, including Virginia's John Brownlee, begin federal investigations. - **2001 — The label changes.** Under mounting FDA pressure, Purdue removes the "believed to reduce the abuse liability" language from the OxyContin label. The marketing in the field continues largely unchanged. - **2003 — DEA investigation intensifies.** The Drug Enforcement Administration's diversion-control program identifies OxyContin as a top-tier diverted drug. State medical boards begin sanctioning "pill mill" physicians, particularly in Florida (which becomes a national hub of fraudulent pain clinics that ship pills to other states). - **2007-05-10 — Purdue Pharma and three executives plead guilty (the first time).** In federal court in Abingdon, Virginia, Purdue Frederick Company (the Purdue-Sackler parent entity) pleads guilty to a felony count of **misbranding** OxyContin — specifically, marketing it as less addictive, less subject to abuse, and less likely to produce withdrawal than other opioids, claims for which there was no clinical evidence and no FDA approval. Three executives plead guilty to misdemeanor misbranding: CEO **Michael Friedman** ($19M individual fine), General Counsel **Howard Udell** ($8M), and Chief Medical Officer **Paul Goldenheim** ($7.5M). Total combined fine: **$634.5 million**. Sentences: probation, 400 hours of community service, no prison time. The Sackler family is not personally charged. - **2007–2010 — The pattern hardens.** Despite the guilty plea, Purdue does not exit the opioid business. Sales continue to grow. Internal Sackler documents (later released during the bankruptcy) show the family pressuring management to push higher doses, to expand the sales force, and to target high-prescribing physicians — including those the company's own data flagged as potential pill-mill operators. [[Richard Sackler]] in 2008: "We have run out of patients to put on opioids. Future growth requires increasing dosage in existing patients." --- ## Era 4 — Heroin Substitution and Big Three Distribution (2010–2015) - **2010 — Reformulated OxyContin (OP).** Purdue introduces a reformulated, abuse-deterrent version of OxyContin that is harder to crush. Within months, surveys show that street users have substituted to **heroin** in large numbers — heroin is cheaper, more available (a Mexican drug-trafficking infrastructure has built up to serve the new market), and easier to consume. The pharmaceutical epidemic and the heroin epidemic are not sequential; they are the same epidemic shifting supply chains. **Wave 2** of the crisis is officially dated to 2010. - **2010 — McKinsey & Company's "turbocharge sales" strategy.** [[McKinsey & Company]], the global management consultancy, advises Purdue on how to "turbocharge the sales" of OxyContin. McKinsey recommends targeting high-prescribing physicians, rebating distributors for OxyContin overdose-linked prescriptions, and other tactics that subsequent state-AG investigations will characterize as actively designed to increase OxyContin sales in regions already experiencing overdose deaths. In 2021, McKinsey will agree to a **$573 million** settlement with state attorneys general — its first-ever such public settlement — and will issue a rare public apology. A former McKinsey senior partner will later be charged with obstruction of justice for destroying records. - **2010–2015 — The Big Three distributors.** **AmerisourceBergen, Cardinal Health, and McKesson** — the three largest US pharmaceutical wholesale distributors, controlling roughly 90% of the market — ship billions of opioid pills into communities of a few thousand residents. The town of Williamson, West Virginia (population 3,000) receives 20.8 million hydrocodone and oxycodone pills over a decade. The Charleston Gazette-Mail will win the 2017 Pulitzer Prize for Investigative Reporting for documenting these flows. The Big Three will eventually settle for **$21 billion** (2021). - **2013 — The fentanyl wave begins (Wave 3).** Illicit fentanyl, primarily manufactured in China and smuggled via Mexico, begins replacing heroin in the US illicit drug supply. Fentanyl is 50–100× more potent than morphine and can be transported and adulterated invisibly. From this point, the **majority of opioid overdose deaths involve illicit synthetic opioids** rather than prescription pills. The Sackler / Purdue role in *initiating* the crisis becomes one step removed from the *current* death curve, but the population of people whose addictions began with prescription opioids is now buying street fentanyl. - **2015 — First state Attorney General lawsuits.** States begin filing civil suits against Purdue Pharma and (increasingly) against individual Sackler family members. Kentucky settles with Purdue for $24 million in 2015. The wave of state and municipal lawsuits builds through 2016–2018 and eventually reaches roughly **2,600 plaintiffs** — states, counties, cities, hospital systems, tribal nations, and individual victims — by 2019. --- ## Era 5 — Litigation and Bankruptcy (2016–2021) - **2016-04 — Sackler family begins large-scale wealth transfers.** Internal documents later released during bankruptcy show that as litigation pressure mounted, the family transferred at least **$11 billion** out of Purdue Pharma between roughly 2008 and 2019 into family trusts, offshore vehicles (in Bermuda, Jersey, Mondaine, and other jurisdictions), and the international affiliated company Mundipharma. The transfers are not concealed — they are documented in audited financial statements — but they are timed, in the aggregate, to remove assets from Purdue's reach before the bankruptcy filing. - **2017 — *New Yorker* exposé.** Patrick Radden Keefe's October 23, 2017 article "The Family That Built An Empire Of Pain" becomes the first major mainstream-media accounting of the Sackler family's central role. It later forms the basis of Keefe's 2021 book *Empire of Pain*, which (with Beth Macy's *Dopesick* and Barry Meier's *Pain Killer*) becomes the standard popular reference on the crisis. - **2017–2019 — Protest movement against Sackler philanthropy.** Artist and photographer Nan Goldin — herself an OxyContin survivor — founds Prescription Addiction Intervention Now (P.A.I.N.) and stages high-profile "die-in" protests at major museums named for the Sacklers: the Metropolitan Museum of Art (Sackler Wing of Egyptian Antiquities), the Guggenheim, the Louvre, the [[Smithsonian Institution]], Tate Modern, the Victoria & Albert. Within roughly four years (2018–2022), most major museums announce they will no longer accept Sackler money, and many remove the family name from existing galleries — including Harvard, the Met, the Louvre, NYU, and Tufts. The family's century-old reputation-laundering project — which dates back to Arthur Sackler's mid-century art collecting — collapses in roughly 18 months. - **2019-09-15 — Purdue Pharma files for Chapter 11 bankruptcy.** Purdue files in the Southern District of New York under Judge Robert Drain. By this point ~2,600 lawsuits are pending. The filing pauses litigation against Purdue itself. The Sacklers — who have not personally filed for bankruptcy — initially demand, and obtain from Judge Drain, broad **nondebtor releases** that would immunize the family from civil opioid liability worldwide in exchange for paying $4.5 billion (later raised to $6 billion+) into the bankruptcy estate. - **2020-10-21 — Purdue's second guilty plea.** Purdue Pharma agrees to plead guilty (in federal court, not bankruptcy court) to a federal **felony**: defrauding the United States and violating the federal Anti-Kickback Statute by, among other things, paying physicians through speaker programs to write more OxyContin prescriptions. Total agreed value of the settlement: **$8.3 billion**. No individual Sackler is charged. The plea is part of the bankruptcy framework: Purdue will be reorganized into a public-benefit company (NewCo) whose profits go to opioid abatement; the Sacklers will give up Purdue but retain Mundipharma and the offshore wealth. - **2021-09 — Initial bankruptcy plan confirmed.** Judge Drain approves a reorganization plan that includes the contested nondebtor third-party release for the Sacklers. The US Trustee — a Justice Department component, headed by William K. Harrington — and several states and individuals object and appeal. --- ## Era 6 — Harrington v. Purdue Pharma and the Renegotiation (2022–2025) - **2022-05 — Second Circuit reverses, then reinstates.** A district court (Judge Colleen McMahon) rules in late 2021 that the nondebtor releases are not permitted. The Second Circuit Court of Appeals reverses in May 2023, holding that bankruptcy courts may approve nondebtor releases in appropriate circumstances. The US Trustee petitions the Supreme Court. - **2023-08-10 — Supreme Court grants cert.** The Court agrees to hear *Harrington v. Purdue Pharma L.P.* and stays the bankruptcy plan pending the decision. - **2023-12-04 — Oral argument.** The argument focuses on whether the Bankruptcy Code permits a Chapter 11 plan to release legal claims that nondebtor claimants hold against nondebtor third parties (here, the Sacklers) without the claimants' individual consent. [[Justice Gorsuch]] presses on whether the Sacklers should get a discharge without putting their assets in the bankruptcy estate. - **2024-06-27 — Supreme Court rules 5–4 against Purdue.** [[Harrington v. Purdue Pharma]] is decided **5–4**. The majority (Justice Gorsuch writing, joined by Justices Thomas, Alito, Barrett, and Jackson — a remarkable cross-ideological alignment) holds that the Bankruptcy Code **does not authorize nonconsensual nondebtor releases**. The Sackler family cannot obtain a release of all opioid claims against them through Purdue's bankruptcy unless the individual claimants consent. The dissent ([[Justice Kavanaugh]], joined by [[Chief Justice Roberts]], [[Justice Sotomayor]], and [[Justice Kagan]]) argues that the ruling will harm opioid victims by destroying the settlement infrastructure. Gorsuch's reply: a debtor "obtains a discharge of debt liability" only by putting "virtually all of its assets" on the table — which the Sacklers did not do. **The settlement collapses.** - **2024-07 to 2025-01 — Six months of renegotiation.** Bankruptcy mediators, plaintiffs' counsel, and the Sacklers negotiate a new framework. Two changes from the prior deal: (1) the Sacklers must pay **more** — $6.5 billion instead of $6 billion — over 15 years; (2) the Sacklers do **not** receive immunity from future opioid lawsuits. Individuals retain their right to sue family members personally; the deal binds only those who opt in. - **2025-01-24 — Revised settlement announced.** State attorneys general announce agreement on a **$7.4 billion** settlement: **$6.5 billion from the Sackler family** (paid over 15 years) + **$900 million from Purdue Pharma** itself. Purdue will be reorganized as a public-benefit company called Knoa Pharma. Sackler payments begin with $1.5B in early 2026, then $500M after one year, $500M after two years, and $400M after three years. - **2025-06-16 — Final agreement.** All 50 states have now signed onto the framework. Purdue files an amended Chapter 11 plan reflecting the new settlement. - **2025-11-14 — Bankruptcy judge confirms the plan.** (Bench ruling; the formal confirmation order was entered Nov 18.) Judge Sean Lane (who took over after Judge Drain retired) approves the $7.4B settlement as the final disposition of Purdue Pharma's bankruptcy. The Purdue Pharma case is now substantively closed at the corporate level. Civil lawsuits against individual Sacklers may still proceed where claimants did not opt into the settlement. - **2026-05-01 — Purdue plan takes effect.** Purdue exits bankruptcy, Knoa Pharma begins operating, and the Sacklers make their first $1.5B payment (Davis Polk; California and Pennsylvania AG announcements). --- ## Era 7 — Aftermath and Continuing Crisis (2024–present) - **2024 — Overdose deaths decline sharply.** Annual US overdose deaths fall from ~107,000 (2023) to ~84,000 (2024). Opioid-involved deaths fall from 79,358 (2023) to 54,045 (2024) — the largest single-year decline since the crisis began. The decline is widely attributed to (a) widespread naloxone (Narcan) distribution, including over-the-counter availability since 2023; (b) increased buprenorphine and methadone treatment access; (c) supply-side disruption of fentanyl precursor chemistry following US-China cooperation agreements; (d) the population of people most at risk having already died. - **2025 — Xylazine and nitazenes proliferate.** New adulterants — xylazine ("tranq"), a veterinary sedative not controlled under the federal Controlled Substances Act, and nitazenes (a class of synthetic opioids potentially more potent than fentanyl) — appear in the illicit supply. Xylazine causes severe necrotic skin wounds and does not respond to naloxone. Public health responses lag. - **2025–2026 — Public-health settlement deployment.** State and local opioid-abatement funds from the various national settlements (Big Three distributors, Johnson & Johnson, Walgreens, CVS, Teva, McKinsey, Purdue) begin reaching local agencies. Total settlement value across all defendants exceeds **$50 billion**. Critics including the Drug Policy Alliance argue that much of the money is being absorbed by law-enforcement budgets and traditional anti-drug infrastructure rather than evidence-based public-health interventions. - **2026 — The Sackler family today.** Forbes (April 2026) estimates the combined wealth of the Mortimer and Raymond Sackler branches at approximately **$11 billion** *after* the settlement payments are netted out — meaning the family's net worth has barely been reduced by the settlement, because most of the payments come from interest and investment returns on the pre-bankruptcy transfers. The reputation-laundering machinery (the Sackler-named museum wings, university buildings, and medical-school endowments) is largely dismantled. No criminal charges have been filed against any individual Sackler. None has served any prison time. The crisis has killed **more than 800,000 Americans** and continues. --- ## Cumulative Stats | Metric | Value | Year | |--------|-------|------| | US opioid-overdose deaths (cumulative) | ~806,000+ | 1999–2023 | | Peak annual opioid-overdose deaths | ~81,800 | 2022 | | 2024 opioid-overdose deaths (sharp decline) | ~54,045 | 2024 | | OxyContin revenue, year 1 | $48 million | 1996 | | OxyContin revenue, year 5 | ~$1.1 billion | 2000 | | Purdue Frederick 2007 plea total fine | $634.5 million | 2007 | | Sackler pre-bankruptcy transfers out of Purdue | ~$11 billion | 2008–2019 | | Big Three distributor settlement | ~$21 billion | 2021 | | McKinsey settlement | $573 million | 2021 | | 2025 final Sackler + Purdue settlement | $7.4 billion | 2025 | | Total cross-defendant opioid settlements | $50+ billion | through 2025 | | Sackler family members criminally charged | 0 | as of 2026 | | Sackler family members imprisoned | 0 | as of 2026 | --- ## Patterns and Through-Lines ### The marketing playbook is older than OxyContin The techniques Purdue used in 1996 — direct-to-physician promotion, sponsored medical education, captured front groups, evidence-free safety claims, sales-rep gifting — were Arthur Sackler's innovations from the Valium era in the 1960s. The OxyContin disaster was the same machinery applied to a more dangerous product. ### Regulatory capture happened at every layer The FDA medical examiner who approved OxyContin's misleading label later worked at Purdue. The Joint Commission incorporated pain-as-vital-sign standards while accepting Purdue funding for educational materials. State medical boards were slow to discipline pill-mill prescribers. The Big Three distributors maintained shipment volumes that any reasonable diversion-control review would have flagged. The DEA's diversion-control program was repeatedly understaffed and politically constrained. ### Bankruptcy almost worked as immunity The original Purdue Chapter 11 plan would have used a corporate bankruptcy to extinguish *individual* civil liability for a wealthy family that had not itself filed for bankruptcy. [[Harrington v. Purdue Pharma]] closed that door — but only after the original plan had been negotiated, blessed, confirmed, and was nearly final. The Supreme Court ruling is now the principal legal protection against future "Sackler-style" use of corporate bankruptcy to shield individual wealth. ### Philanthropy is a reputation laundromat The Sackler-named museum wings, university buildings, medical-school endowments, and medical-research grants were not incidental to the family's wealth strategy. They were a deliberate part of it — the third leg of a Carnegie-Rockefeller-Mellon template that converts contested commercial wealth into uncontested civic legitimacy. See [[Andrew Mellon]] for the historical archetype. The Nan Goldin-led protest movement collapsed that machinery in roughly four years. ### The class asymmetry with the War on Drugs is total A corporation that fueled an epidemic killing 800,000 Americans paid fines, restructured in bankruptcy court, and produced zero criminal sentences for its owners. Individual users of crack cocaine — a less-addictive substance than the prescription opioids Purdue marketed — received decades of mandatory-minimum federal prison time during the same decades. See [[War on Drugs Timeline]] for the parallel carceral track. --- ## See Also - [[Sackler Family]] — the dynasty entity (founders, branches, current state) - [[Purdue Pharma]] — the corporate entity - [[OxyContin]] — the drug itself - [[Harrington v. Purdue Pharma]] — the 2024 Supreme Court ruling - [[Pseudoaddiction]] — the term used to justify dose escalation - [[McKinsey & Company]] — the management consultancy that designed the "turbocharge" sales strategy - [[War on Drugs Timeline]] — the parallel carceral story - [[Letitia James]] — NY AG, $1.5B individual state settlement - [[Andrew Mellon]] — the historical philanthropy-as-laundering archetype